Is DBV Technologies S.A. (DBVT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.6% / 30% | 2.7% / 30% | 0.9% / 30% | N/A | ✓ HALAL |
| DJIM | 0.6% / 33% | 2.7% / 33% | 0.9% / 33% | N/A | ✓ HALAL |
| MSCI | 11.9% / 33% | 49.4% / 33% | 15.8% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.6% / 33% | 2.7% / 33% | 0.9% / 33% | N/A | ✓ HALAL |
| FTSE | 11.9% / 33% | 49.4% / 33% | 15.8% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -1235.7% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -234.1% | |
| Return on Assets (ROA) | -77.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$104M |
| Free Cash Flow | -$107M |
| Total Debt | $8M |
| Debt-to-Equity | 14.6 |
| Current Ratio | 1.8 |
| Total Assets | $66M |
Price & Trading
| Last Close | $20.21 |
| 50-Day MA | $21.54 |
| 200-Day MA | $14.88 |
| Avg Volume | 346K |
| Beta | -0.2 |
|
52-Week Range
$5.75
| |
About DBV Technologies S.A. (DBVT)
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is DBV Technologies S.A. (DBVT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), DBV Technologies S.A. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is DBV Technologies S.A.'s debt ratio?
DBV Technologies S.A.'s debt ratio is 0.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.9%.
What are DBV Technologies S.A.'s key financial metrics?
DBV Technologies S.A. has a market capitalization of $1.1B. Return on equity stands at -234.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.